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under the CC BY license (http://creaSummary Objective: Bacterial meningitis in sub-Saharan Africa is predominantly caused by
Streptococcus pneumoniae, is often associated with HIV co-infection and mortality rates are
double those seen in better resourced settings.
Methods: To investigate the cause of this excessive mortality we quantified the pneumococcal
DNA load and six common pro-inflammatory cytokines in the cerebrospinal fluid (CSF) of Mala-
wian adults with culture proven pneumococcal meningitis and correlated the results to clinical
parameters and outcome. There are currently no published data relating bacterial load to
outcome in adults with pneumococcal meningitis.
Results: The mean age of patients was 32 years, 82% were HIV infected and 49% had died by
day 40. CSF bacterial loads were high (median 6.5  105 copies/ml CSF) and there was no sig-
nificant variation in bacterial load between survivors and non-survivors. All pro-inflammatory
CSF cytokines were elevated in the CSF, with no clinically important differences between sur-
vivors and non-survivors. HIV status did not affect the CSF bacterial load or cytokine response.
Conclusion: Mortality from pneumococcal meningitis in adults in sub-Saharan Africa is notrpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. Tel.: þ265 1875918, þ265
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Mortality from pneumococcal meningitis 441related to pneumococcal bacterial load. More research is needed to understand the very high
mortality from meningitis in this region.
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The incidence of pneumococcal meningitis in adults is
estimated to be 0.1e1/100,000 in well-resourced coun-
tries1,2; in sub-Saharan Africa where there are few surveil-
lance data, the incidence is estimated to be 12/100,000
adult population3. In addition to the increased burden of
disease in this region, the adult mortality rate from pneu-
mococcal meningitis is 54%, compared to 30% in Europe.4,5
High Streptococcus pneumoniae bacterial load in the cere-
brospinal fluid (CSF) has been associated with increased
mortality in children with meningitis in Malawi and
Finland, higher bacterial loads in the blood of adults with
pneumococcal sepsis in Europe are also associated with
poor outcome.6e8 Pro-inflammatory cytokines are elevated
in the CSF of adults with bacterial meningitis compared to
viral meningitis9,10 but little data are available to deter-
mine if elevated CSF cytokines are associated with
outcome from meningitis in adults. We examined the asso-
ciation between pneumococcal load and host cytokine
response and mortality from pneumococcal meningitis in
Malawian adults.Methods
Study participants
Patients aged >16 years with bacterial meningitis were
recruited into one of two sequential randomised placebo
controlled clinical trials of adjuvant therapy between 2001
and 2004 (dexamethasone, placebo) or 2006e2008 (glyc-
erol, placebo)11,12 conducted at Queen Elizabeth Central
Hospital, Malawi. CSF samples taken prior to antibiotic
and adjuvant therapy were transported immediately to
the laboratory where a cell count was performed. If the
cell count met the inclusion criteria for the contributing
clinical trial (>100 cells/mm3 with >50% neutrophils),11,12
CSF supernatant was frozen at 80 C within 2 h of lumbar
puncture. The laboratory at the Malawi-Liverpool-
Wellcome Trust clinical research programme has provided
an externally quality-controlled microbiology service to
QECH since 2000 www.mlw.medcol.mw. Diagnostic CSF
was cultured on blood agar at 37 C in 5% CO2. S. pneumo-
niae was identified by standard methods including optochin
sensitivity and alpha haemolysis. Only culture positive sam-
ples for S. pneumoniae were included in this study, molec-
ular diagnostics using PCR were not available. Treatment of
pneumococcal meningitis was ceftriaxone 2 g twice daily
for 10 days. A second CSF sample was taken 48 h post anti-
biotic therapy in a sub-set of patients, some of whom were
treated with intramuscular as opposed to intravenous cef-
triaxone as per protocol of the dexamethasone clinicaltrial. Poor outcome was defined as death by 6 weeks of
follow up. Morbidity data were not available.
Real time PCR for S. pneumoniae
DNA was extracted from 200 ml of pneumococcal culture
positive CSF supernatant and Real-Time PCR was performed
as described previously using autolysin (LytA) as the ampli-
fication target.13 Standard curves were created using puri-
fied genomic DNA extracted from S. pneumoniae serotype
23F (P833), and quantified using the NanoDrop ND-1000.
Cytokine analysis
Six cytokines IL1b, IL6, IL10, IL8, IL12 and TNFa were
measured using a cytometric bead array (BD Biosciences,
San Diego). Six bead populations with differing 650 nm
fluorescence intensities were coated with cytokine specific
capture antibodies and incubated with flourochrome
(phycoerythrin e 585 nm) according to the manufacturer’s
instructions. The resulting sandwich complexes were
resolved in the FACScan flow cytometer and the output
analysed using manufacturer’s software.
Ethics
Participants or accompanying legal guardians gave written
informed consent for CSF samples to be stored and used for
research studies. Both constituent studies were granted
ethical approval for sample collection and analysis by the
Liverpool School of Tropical Medicine Research Ethics
Committee and the College of Medicine Research Ethics
Committee, University of Malawi.
Statistics
Statistical analysis was done using IBM SPSS statistics
version 20. Graphs were generated using GraphPad PRISM
version 5. Median (inter-quartile range) was used to sum-
marise non-normally distributed variables, while mean (SD)
was used to summarise normally distributed variables.
Statistical tests were 2 tailed, non-parametric tests were
used to analyse data that were not normally distributed. A
t-test was used to analyse normally distributed variables.
Categorical variables were analysed using Fisher’s exact
test. A multivariate model was generated using binary logis-
tic regression, enter mode, and cross checked using
backwards LR mode. Clinical variables entered into the
multivariate model were chosen based on previous associa-
tion with poor outcome.4 Statistical significance was deter-
mined at a value of <0.05 and 95% confidence intervals for
the odds ratios have been provided. Day 40 was used as the
outcome measure for all analyses.
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Data were collected from 151 patients with stored CSF
samples and paired clinical data. Data were available for all
patients to day 10; day 40 outcome data were missing for 3
patients who were lost to clinical follow up.
Baseline characteristics of the included patients are
shown in Table 1. The mean age was 32 years (IQR 25e36);
51% were female and 82% were HIV-antibody positive of
which only 2 were on Antiretroviral therapy (ART)
(Table 1). The overall mortality was 63/151 (41%) at day
10 and 73/148 (49%) at day 40. Data on sequelae in survivors
were not available for analysis. Median CSF white cell count
(WCC) was 760 cells/mm3 (IQR 181e2600) with significantly
higher WCCs in survivors compared to non-survivors
p Z 0.02 on univariate analysis (Table 1). The median CSF
bacterial load was 6.5  105 copies/ml (IQR
1.08  105e2.96  106) in the admission samples and
2.96  104 copies/ml (IQR 3.8  103e2.12  105) in the
CSF samples taken 48 h post antibiotics (Fig. 1a). There
was no difference in the bacterial load between survivors
or non-survivors at presentation or at 48 h (p Z 0.52 and
0.65 respectively, Table 1). In addition there was no signif-
icant difference in the magnitude of the decline in the bac-
terial load between survivors and non-survivors over 48 h.
An ROC curve was synthesised to assess if bacterial loads
>1  106 copies/ml predicted poor outcome; the area un-
der the curve (AUC) was 0.49 (non-significant, curve not
shown).
Six common cytokines were measured in the CSF. Overall
there was an intense pro-inflammatory cytokine response in
the CSF of all patients; no differences by day 40 outcome
reached statistical significance on univariate analysis
(Supplementary Table 1, Fig. 1b). Two multivariate models
were synthesised to investigate the influence on outcome
of bacterial load (model 1) and cytokine response (model
2). Two models were required as there were insufficient pa-
tients with both bacterial load and cytokine data (n Z 18)
to combine into a single model. No statistically significant
mortality association was demonstrated for the CSF bacte-
rial load or CSF white cell count, HIV status, age or gender
on model 1 (n Z 102); seizures at any time in the illness,
GCS or altered mental status and anaemia were associated
with mortality (Table 1). In model 2 (n Z 62) IL8 and IL10
were marginal predictors of non-survival; IL8 p Z 0.036,
OR 1.00 (95% CI 1.00: 1.00) and IL10 p Z 0.029, OR 1.00
(95% CI 1.00 : 1.00); of the clinical parameters, only altered
mental status or GCS retained significance in this model
(Supplementary Table 1).
Discussion
We have previously shown that coma, seizures and anaemia
predict poor outcome from bacterial meningitis in Malawi,5
but the causes of the excess mortality compared to pa-
tients in more well-resourced settings remain unclear. In
this study, there was no difference in the bacterial load
and only marginal difference in the cytokine response be-
tween survivors and non-survivors despite lower CSF white
cell counts in non-survivors. Our findings are markedly
different to data in children with pneumococcal meningitisin Malawi and Europe, and adults with pneumococcal bac-
teraemia in Europe or meningococcal meningitis in the
UK.6e8,14 No published data has quantified CSF pneumo-
coccal load in adults with meningitis in either setting.
The lack of association between outcome and pneumo-
coccal load, in contrast to these other studies was unex-
pected. HIV uninfected adults with pneumococcal
meningitis in Europe have a 10 fold higher CSF WCC than
our patients, a CSF WCC of <1000 cells/mm3 has been
shown to be significantly associated with mortality in Eu-
rope.4 In our study, the median CSF WCC was substantially
below this threshold, and low CSF WCCs were associated
with poor outcome. We hypothesise that in adults with
pneumococcal meningitis in Malawi, rapid bacterial growth
occurs within the CSF with relatively little restriction by the
host immune response, leading to high bacterial loads in
both outcome groups. In addition, delays from symptom
onset to admission in the community and to lumbar punc-
ture within the hospital system may have resulted in the
bacterial growth reaching the plateau, as opposed to the
exponential growth phase in the CSF by the time of lumbar
puncture, and hence any differences between outcome
groups may have equalised by the time of examination.
Time from symptom onset to lumbar puncture in the
included studies was 3e5 days, compared to <48e72 h
for most European studies.11,12,15e17
Adults with pneumococcal meningitis in Malawi have
different baseline characteristics compared to those stud-
ied in other settings outside of sub-Saharan Africa,4,5 and
disease is caused disproportionately by serotype one.18
Data from studies of pneumococcal meningitis in this region
may not be directly comparable to data from other regions.
Adults with bacterial meningitis in Malawi are commonly
HIV co-infected, they present late to hospital and they
experience in-hospital delays to lumbar puncture and anti-
biotic treatment.5,19 82% of the patients in our study were
HIV-antibody positive compared to 62% of children with
pneumococcal meningitis in Malawi and 0% from the Euro-
pean series.6,7 The CSF levels of six common cytokines in
our patients were much higher than those observed at base-
line in predominantly HIV-uninfected adults with bacterial
meningitis in other centres,9,20,21 although we cannot
exclude the possibility that a pro-inflammatory effect of
untreated HIV infection is contributing to the cytokine re-
action observed, as the numbers of HIV un-infected pa-
tients in our study were small.17 Minimal data exist
correlating cytokine levels with poor outcome in a small
number of patients with meningitis, no HIV co-infected pa-
tients were included in that cohort.9 CSF cytokine levels in
our study did not vary by adjunct or placebo in either trial,
dexamethasone had no effect on outcome.11
The paediatric study in our centre, where 62% of
children where HIV co-infected, demonstrated an equally
intense CSF cytokine response in children with pneumo-
coccal meningitis; the four cytokines measured in that
study (TNFa, IL-1b, IL-6 and IL-10) were significantly higher
only in HIV co-infected non-survivors as compared to HIV
co-infected survivors.5 HIV status is not a predictor of poor
outcome in adults with pneumococcal meningitis in
Malawi,4 although it is well established that HIV infection
is an important risk factor for invasive pneumococcal dis-
ease (IPD) in sub-Saharan Africa.18
Table 1 Baseline characteristics for patients with culture-confirmed pneumococcal meningitis and CSF bacterial load values (n Z 102). Multivariate analysis presented for
Model 1, clinical parameters with bacterial load data.
Clinical parameter (n Z data available) All participants
(SD, IQR or %)
Survivor day 40
(SD, IQR or %)n Z 75
Non-survivor day 40
(SD, IQR or %)n Z 73
Survival
significance
(univariate)
Odds ratio
(95% CI)
bacterial
load data
Model 1
Survival significance
bacterial load
model 1 n Z 102
(multivariate)
Female gender n Z 144 72 (51%) 36 (48%) 36 (49%) 0.4c 2.24
(0.62:8.03)
0.21
Mean age n Z 144 32.1 (SD 9.7) 30 (SD 9.1) 33 (SD 10.2) 0.06a 1.02
(0.95:1.09)
0.54
HIV antibody positive n Z 141 115 (82%) 60 (80%) 55 (75%) 0.8c 1.43
(0.25:8.2)
0.68
Seizures n Z 142 50 (35%) 16 (21%) 34 (47%) 0.002c 7.2
(2.18:23.8)
0.001
Altered mental state GCS <15 111 (81%) 49 (65%) 61 (84%) <0.001c 4.55
(0.41:51.0)
0.22
Median Glasgow coma score (GCS) n Z 137 11 (8e14) 13 (10e15) 9 (7e11) <0.001b 0.72
(0.59:0.92)
0.001
Dexamethasone n Z 89 49/89 (55%) 28 (57%) 21 (43%) 0.36c 0.47
(0.12:1.87)
0.28
Glycerol n Z 62 27/62 (46%) 8 (30%) 19 (70%) 0.03c 2.29
(0.4:12.9)
0.34
Mean Haemoglobin (g/dL) n Z 129 11.3 (SD 2.9) 11.3 (SD 2.4) 11.4 (SD 3.2) 0.94a 0.82
(0.68:0.98)
0.032
Median CSF white cell count (mm3/ml) n Z 143 760 (181e2600) 1120 (320e1320) 370 (105e1480) 0.021b 1.0
(1.0e1.0)
0.91
Median CSF bacterial load
(DNA copies/ml) with IQR
Admission n Z 102 6.5  105
(1.08x105e2.96  106)
8.10  105
(4.74  104e3.24  106)
5.94  105
(1.59  105e2.42  106)
0.52b 1.0
(1.0e1.0)
0.64
48 h post antibiotics n Z 42 2.9  104
(3.8x103e2.12  105)
2.72  104
(4.12  103e2.43  105)
7.96  104
(1.56  103e2.19  105)
0.64b 1.0
(1.0e1.0)
0.22
a t-test.
b ManneWhitney-U test.
c Fisher exact test/Chi-squared test.
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Figure 1 CSF parameters in adults with pneumococcal meningitis in Malawi. Bars indicate median with range. 1a log 10 CSF bac-
terial load in survivors and non-survivors at 10 and 40 days post admission to hospital and CSF bacterial load in day 40 survivors and
non survivors at admission and 48 h post antibiotic treatment. 1b CSF cytokine levels in survivors and non-survivors at day 40 paired
by cytokine measured with full range.
444 E.C. Wall et al.We have previously reported results of a major proteo-
mic analysis of Malawian adults with bacterial meningitis.22
Although increased CSF protein spots were associated with
non-survival, no differences in the host proteomic response
other than complement and ferritin responses were noted.
In addition we have observed that the persistence of pneu-
molysin in the presence of a falling bacterial load and low
CSF complement C3 were associated with higher mortality
in a small number of patients with pneumococcal meningi-
tis.12,15 Those data, combined with the observations in this
study of lower WCC and higher cytokines in the CSF, suggest
that poor outcome may be due more to abnormalities of the
host response to S. pneumoniae than excessive virulence of
the pathogen.13,23 CSF co-infection with EpsteineBarr virus
has also been shown to correlate with poor outcome
in adults with bacterial meningitis in Malawi.24 We arecurrently investigating whether lower CSF WCCs are associ-
ated with viral co-infection. In addition, the influence of
significant pre-hospital and clinical delays on outcome has
not been fully quantified.5,13
Limitations exist within our data. Firstly, the small
numbers of patients with both CSF genomic load and
cytokine data available precluded a definitive analysis of
bacterial load and cytokine levels in the same statistical
model. Secondly, data for sequelae in survivors were not
available, the different scoring systems used in the
included studies meant significant heterogeneity in the
outcome data precluded analysis of the impact of bacterial
load or cytokine response on morbidity from meningitis.
In conclusion, poor outcome from pneumococcal
meningitis in Malawi is likely to be multifactorial and our
data suggest that anti-cytokine adjunctive treatments in
Mortality from pneumococcal meningitis 445sub-Saharan Africa are unlikely to be effective. Alternative
strategies such as pneumococcal vaccination in HIV in-
fected adults, reducing pre-hospital delays to treatment,
optimising in-hospital care, investigating alternative
adjunctive treatments targeting pneumococcal toxins and
optimising macrophage phagocytosis13,23,25e27, should be
on-going research priorities.
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